Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Nora Ruel

5PUBLICATIONS

24CO-AUTHORS

Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersPacific Peoples psychology

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (5)

Sort by Publication Date:

|Dec 30, 2025

Correction: Senguttuvan et al. The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol Acetate. <i>Antioxidants</i> 2025, <i>14</i>, 345.

Rosemary N Senguttuvan, Hyejin Cho, Xiwei Wu

|Jun 23, 2025

Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer.

Alexis LeVee, Esther Peluso, Melissa G Lechner

|Apr 24, 2024

Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis.

Alexis LeVee, Megan Wong, Sarah Flores

|Nov 30, 2023

Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer.

Ferdynand J Kos, Paul Frankel, Mihaela Cristea

|Jan 04, 2021

Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials.

Ramy Sedhom, Betty Ferrell, Nora Ruel

Pageof 1

Frequent Collaborators

2 joint publications

Raechelle Tinsley

2 joint publications

Alexis LeVee

2 joint publications

Thanh H Dellinger

1 joint publications

Ramy Sedhom

1 joint publications

Betty Ferrell

1 joint publications

Thomas J Smith

1 joint publications

Ferdynand J Kos

1 joint publications

Paul Frankel

1 joint publications

Mihaela Cristea

1 joint publications

Melissa Eng

Frequent Collaborators

2 joint publications

Raechelle Tinsley

2 joint publications

Alexis LeVee

2 joint publications

Thanh H Dellinger

1 joint publications

Ramy Sedhom

Top Related Videos

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on : Sep 12, 2019

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on : Jan 19, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on : May 24, 2024

See more related videos

Top Related Videos

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on : Sep 12, 2019

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on : Jan 19, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on : May 24, 2024

See more related videos